Prophylactic Effect of Probiotic Streptococcus Salivarius eK12 Against Recurrent Streptococcus Pyogenes Pharyngotonsillitis Infection in Pediatrics

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-12-01

Study Completion Date

2026-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Recurrent Group A Streptococcus (GAS) infections, primarily presenting as strep throat, are a significant health concern in pediatric populations, leading to symptoms like sore throat, fever, and swollen lymph nodes. GAS is highly contagious and can spread easily among children in close-contact environments like schools and daycare centers, often resulting in frequent re-infections. Managing these recurrent infections typically requires antibiotics, but reliance on antibiotics carries risks, including resistance development, gut microbiota disruption, and various side effects. Probiotic therapy, particularly with Streptococcus salivarius K12, has shown promise as a preventive approach, utilizing competitive exclusion and antimicrobial production to inhibit GAS growth in the oral cavity. Recent studies have advanced this with the development of S. salivarius eK12, a re-engineered strain that enhances efficacy against GAS by preventing the survival-promoting interactions between the probiotic and pathogenic bacteria. This modified strain, now registered as Bactoblis® EVOL in Italy (EU), holds potential as an effective version to reduce the incidence and severity of GAS infections without the drawbacks of antibiotic therapy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Probiotic S. Salivarius K12 for the Prevention of Upper Respiratory Tract Infection in Nursery-age Children

NCT05840926

Upper Respiratory Tract Infection

COMPLETED NA

Evaluation of Safety and Human Tolerance of Oral Probiotic Streptococcus Salivarius eK12

NCT06380270

Safety Tolerability

COMPLETED NA

The BLIS Study: a Feasibility Study Assessing Compliance, Acceptability and Colonisation With Different Dosing Regimens of the Probiotic Supplement Streptococcus Salivarius K12 (Bactoblis®) in Adults

NCT04297878

Sore Throat Tonsillitis Pharyngitis

UNKNOWN NA

Study to Investigate the Treatment Benefits of Probiotic Streptococcus Salivarius K12 for Hospitalised Patients (Non-ICU) With COVID-19

NCT05043376

Covid19

COMPLETED NA

The Effectiveness of Probiotics for the Therapy of Acute Pharyngotonsillitis in Adult Patients

NCT01679366

Throat Pain

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The primary aim of this clinical trial is to evaluate whether prophylactic use of S. salivarius eK12 can effectively reduce the frequency and severity of strep throat episodes in children. By assessing the efficacy of S. salivarius eK12 supplementation, this study seeks to provide insights into its potential as a non-antibiotic preventive strategy for recurrent strep throat infections in pediatric populations.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Streptococcus Pyogenes Pharyngotonsillitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Probiotic supplement group

Participants in this group will receive probiotic Streptococcus salivarius eK12 (Bactoblis® EVOLcontaining ca. 1 billion CFU of Streptococcus salivarius eK12/capsule) as daily one capsule (to be slowly dissolved in the mouth before sleeping at night time) for 3-months. There will be a further 3-months follow-up period.

Group Type EXPERIMENTAL

Probiotic Bactoblis® EVOL (Streptococcus salivarius eK12)

Intervention Type DIETARY_SUPPLEMENT

Bactoblis® EVOL: containing one billion CFU of probiotic Streptococcus salivarius eK12

Control group

Participants in this group will not receive probiotic Streptococcus salivarius eK12 (Bactoblis® EVOL).

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Probiotic Bactoblis® EVOL (Streptococcus salivarius eK12)

Bactoblis® EVOL: containing one billion CFU of probiotic Streptococcus salivarius eK12

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Children aged 3-10 years.
* Recent history of documented recurrent episodes of Streptococcus pyogenes pharyngo- tonsillitis infection in the last 6 months, or 4 or more episodes in the last 12 months (S.

pyogenes infection being defined as: McIsaac score with clinical score ≥ 2 plus confirmation of S. pyogenes presence with rapid throat swab (RAD) method or McIsaac score =5.

* Willingness to comply with the study protocol and attend scheduled follow-up visits.
* Written informed consent obtained from the parent or legal guardian.

Exclusion Criteria

* Children with known allergies or hypersensitivity to probiotics or any components of the study product.
* Current use of antibiotics or within the past 30 days.
* Used oral colonizing probiotics in the last 6 months.
* Presence of severe underlying medical conditions affecting the immune system or gastrointestinal tract.
* Participation in other clinical trials involving investigational drugs or interventions.
* Inability to adhere to the study requirements due to logistical or social reasons.
* History of rheumatic disorders, bronchospasm, severe asthma, or allergy requiring corticosteroids.
* Past tonsillectomy or an indication for adeno-tonsillectomy; or severe respiratory or systemic disorders
* Individuals immunocompromised or had a condition favouring recurrent Acute Otitis Media (AOM), including severe atopy, acquired or congenital immunodeficiency, cleft palate, craniofacial abnormalities, obstructive adenoids, a chronically ruptured eardrum, sleep apnoea, or tympanostomy tubes
* Children undergoing current pharmacological therapies to prevent recurrent respiratory infections.
* Any other medical condition or circumstance that, in the investigator's judgment, would compromise the safety of the participant or the integrity of the study.

Minimum Eligible Age

3 Years

Maximum Eligible Age

10 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes